The company develops a cancer therapy and early diagnosis for Pnacreatic cancer (PDAC) and Tri-Negative Breast cancer (TNBC) based on Klotho hormon....
The company develops a cancer therapy and early diagnosis for Pnacreatic cancer (PDAC) and Tri-Negative Breast cancer (TNBC) based on Klotho hormon.
More information

Employees

Meir Azulay
Admin
Meir Azulay 33 years in biopharma- 18 in management position in Merck-Serono; since 2005, founder and CEO of CMO and start-ups